“Not an easy thing to estimate, IV growth. However I think that browsing Morningstar data, with no analysis on my part, gives some indication.”
I asked Morningstar if they would consider including trailing fair value growth rate in their screens and portfolios. They said that they would look into it. For now one has to calculate FV growth rate company-by-company using the graph in the “price vs fair value” tab. I can’t claim that screening by FV growth rate is better than screening by ROE or sale growth, but price does track Morningstar’s FV estimates reasonably well.
Here are a few more FV growth rates, not adjusted for dividend, using Morningstar’s estimates of FV. I picked the companies non-randomly. The FV growth rates are not adjusted for dividend. It will be tedious to try to find a portfolio of 25 companies with high FV growth rate, and the merit of doing so is not proven. Anyway, FWIW.
company, trailing 5-year annualized FV growth, P/FV as of Dec '21
MSFT, 40%, 0.97
AMZN, 35%, 0.81
GOOG, 33%, 0.83
AAPL, 30%, 1.39
TECHY, 28%, 0.58
MA, 25%, 1.05
FB, 24%, 0.82
DE, 21%, 1.27
APD, 20%, 0.89
SWKS, 18%, 0.74
LOW, 17%, 1.40
AXP, 16%, 1.04
INTC, 16%, 0.79
BAC, 14%, 1.17
BAX, 14%, 1.0
BRK.A, 13%, 1.0
BABA, 12%, 0.63
KO, 6%, 1.00
JNJ, 8%, 1.02%
PEP, 8%, 1.13
DLTR, 5%, 1.33
MMM, 2%, 0.95
BIIB, 2%, 0.66
BMY, -1%, 0.9
KHC, -6%, 0.72
Do you think that screening for high FV growth rate has merit? I do think that screening for high ROE and high revenue growth rate has merit.